Nanexa AB (publ) (STO:NANEXA)

Sweden flag Sweden · Delayed Price · Currency is SEK
3.760
-0.030 (-0.79%)
Apr 28, 2026, 5:24 PM CET
160.75%
Market Cap 618.84M
Revenue (ttm) 55.94M
Net Income (ttm) -11.39M
Shares Out 164.59M
EPS (ttm) -0.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 211,548
Average Volume 502,510
Open 3.800
Previous Close 3.790
Day's Range 3.705 - 3.815
52-Week Range 1.392 - 5.000
Beta 1.86
RSI 48.51
Earnings Date Apr 29, 2026

About Nanexa AB

Nanexa AB (publ), a pharmaceutical company, develops injectable drug products in the Nordic countries, Europe, Asia, and North America. The company offers PharmaShell, a drug delivery system based on atomic layer deposition coating technology for controlled release of various types of active pharmaceutical substances. It also develops NEX-22, a glucagon-like peptide-1 analogue liraglutide that has completed Phase I trial for the treatment of type 2 diabetes; NEX-18, a drug from azacitidine to treat myelodysplastic syndrome; and NEX-20, a drug f... [Read more]

Sector Healthcare
Founded 2007
Employees 15
Stock Exchange Nasdaq Stockholm
Ticker Symbol NANEXA
Full Company Profile

Financial Performance

In 2025, Nanexa AB's revenue was 55.94 million, an increase of 19.80% compared to the previous year's 46.69 million. Losses were -11.39 million, -54.27% less than in 2024.

Financial Statements

News

Nanexa AB Transcript: Business Update

5 years ago - Transcripts